Finch Therapeutics Group Inc
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in hu… Read more
Finch Therapeutics Group Inc (FNCH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.332x
Based on the latest financial reports, Finch Therapeutics Group Inc (FNCH) has a cash flow conversion efficiency ratio of -0.332x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.73 Million) by net assets ($14.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Finch Therapeutics Group Inc - Cash Flow Conversion Efficiency Trend (2019–2023)
This chart illustrates how Finch Therapeutics Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Finch Therapeutics Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Finch Therapeutics Group Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BRIDGETEC Corp
KQ:064480
|
0.030x |
|
Molecure S.A.
WAR:MOC
|
0.266x |
|
Gencurix Inc
KQ:229000
|
-0.140x |
|
Columbus
WAR:CLC
|
0.387x |
|
Beta Drugs Ltd.
NSE:BETA
|
N/A |
|
Abico FS Co Ltd
TWO:8071
|
0.004x |
|
Tridomain Performance Materials PT
JK:TDPM
|
0.076x |
|
Success Prime Corp
TW:2496
|
-0.072x |
Annual Cash Flow Conversion Efficiency for Finch Therapeutics Group Inc (2019–2023)
The table below shows the annual cash flow conversion efficiency of Finch Therapeutics Group Inc from 2019 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $22.89 Million | $-31.50 Million | -1.377x | -76.02% |
| 2022-12-31 | $95.71 Million | $-74.85 Million | -0.782x | -135.58% |
| 2021-12-31 | $202.22 Million | $-67.13 Million | -0.332x | -201.43% |
| 2020-12-31 | $-95.72 Million | $-31.33 Million | 0.327x | +12.51% |
| 2019-12-31 | $-59.53 Million | $-17.32 Million | 0.291x | -- |